Chapter 21 of 25
- Confirm pathology, extent and prior treatment
- Integrate molecular group and recurrence risk
- Discuss intent, benefits, harms and patient priorities
- Agree a multidisciplinary plan and reassessment
What you will learn
- Distinguish vaginal, pelvic and distant recurrence.
- Understand why previous radiation and immunotherapy matter.
- Prepare for a discussion of treatment goals and clinical trials.
Confirming the diagnosis
New bleeding, pain, cough, swelling or weight loss can have several causes. Imaging identifies suspicious areas, and biopsy is often useful when feasible, particularly if the finding is unusual or would change treatment intent. A new lesion is not automatically recurrence; it could be benign or another primary cancer. Comparing current tissue with the original report can clarify the diagnosis.
The team reviews the interval since treatment, sites of disease, symptoms, fitness and complete treatment history. Bring the previous radiation plan, systemic treatment record and molecular results when changing hospitals. Retesting selected biomarkers can be helpful if old tissue was inadequate, results were uncertain or a new treatment requires a specific assay.
Local vaginal or pelvic recurrence
An isolated vaginal recurrence without previous pelvic radiation can sometimes be treated with curative-intent external-beam radiation and brachytherapy. The size, depth and nearby-organ involvement affect the plan. Surgery is useful in selected situations, but is not automatically preferable to radiation.
After previous radiation, options become more complex. Specialist reirradiation, surgery or systemic treatment may be considered. Extensive pelvic surgery can carry major effects on bowel, bladder and sexual function, and requires careful selection and counselling. A specialist centre should review the likelihood of complete treatment, morbidity and alternatives before an irreversible decision.
Distant disease and systemic options
| Previous treatment context | Questions for the team |
|---|---|
| No prior systemic treatment for advanced disease | Is chemotherapy–immunotherapy appropriate under the relevant label? |
| Prior platinum, no prior checkpoint inhibitor | Does MMR status support single-agent immunotherapy or another regimen? |
| pMMR disease after systemic treatment | Is lenvatinib–pembrolizumab suitable, and what are its monitoring needs? |
| Progression after immunotherapy | What evidence supports the proposed sequence, and is a trial available? |
| Low-grade receptor-positive slow disease | Could hormonal treatment provide useful control with acceptable burden? |
A long interval after platinum may support considering platinum again in selected patients, but there is no universal rule that makes retreatment effective. Residual neuropathy, kidney function and previous response matter. HER2-directed or tumour-agnostic options require the correct biomarker and indication.
The uncertainty after immunotherapy
Many pivotal later-line studies enrolled patients before first-line checkpoint inhibition became common. Their results cannot simply be assumed to apply after chemo-immunotherapy. Switching between PD-1 antibodies is not a proven general way to overcome resistance. Adding another drug may be reasonable in selected circumstances, but the evidence, regional guidance and alternatives should be explained honestly.
Clinical trials may test new immune combinations, antibody-drug conjugates or molecularly selected strategies. Ask whether the trial is randomized, what standard options remain, what visits are required and who pays for associated care. Participation is voluntary and can be declined without losing ordinary treatment support.
Symptoms, priorities and questions
Palliative care can help with pain, bleeding, nausea, bowel or urinary problems and emotional distress while treatment continues. Ask what outcome matters most: tumour shrinkage, symptom relief, longer control or fewer hospital visits. A plan should include when benefit will be reassessed and when changing or stopping treatment would be appropriate. Recurrence is serious, but it does not mean that every useful option has been exhausted.
Related chapters
- Side Effects and Supportive Care
- Molecular Classification: The Four Major Groups
- How Doctors Choose Treatment
References and review status
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
- KEYNOTE-775 updated efficacy and safety, JCO 2023
- FDA regular approval of dostarlimab monotherapy / GARNET, 2023
- ASCO Palliative Care guideline update, 2024
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy